Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors

American Journal of Medicine

Volumn 106, Issue 5, 1999, Pages 544-549

  Kohno, Masakazu ^a   Yokokawa, Koji ^a   Minami, Mieko ^a   Kano, Hiroaki ^a   Yasunari, Kenichi ^a   Hanehira, Takao ^a   Yoshikawa, Junichi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA; ENALAPRIL; LISINOPRIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 0033134676     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00067-4     Document Type: Article

References (36)

1. MacMahon S., Collins G., Rautaharju P., et al. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the Multiple Risk Factor Intervention Trial. Am J Cardiol. 63:1989;202-210.
2. Multiple Risk Factors Intervention Trial Research Group . Multiple risk factor intervention trial risk factor changes and mortality results. JAMA. 248:1982;1465-1477.
3. Koren M.J., Devereux R.B., Casale P.N., et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352.
4. Schunkert H., Dzau V.J., Tang S.S., et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied hearts. Circulation. 87:1993;1328-1339.
5. Schunkert H., Dzau V.J., Tang S.S., et al. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overloaded left ventricular hypertrophy effects on coronary resistance, contractility and relaxation . J Clin Invest. 86:1990;1913-1920.
6. Dahlöf B., Pennert K., Hannson L. Reversal of left ventricular hypertrophy in hypertensive patients a metaanalysis of 109 treatment studies . Am J Hypertens. 5:1992;95-110.
7. Naftilan A.J., Pratt R.E., Dzau V.J. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1419-1424.
8. Baker K.M., Aceto J.F. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol. 259:1990;H610-H618.
9. Sadoshima J., Xu Y., Slayter H.S., et al. Autocrine release of angiotensin II mediated stretch-induced hypertrophy of cardiac myocyte in vivo. Cell. 75:1993;977-984.
10. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme levels. J Clin Invest. 86:1990;1343-1346.
11. Schunkert H., Hense H.-W., Holmer S.R., et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. NEJM. 330:1994;1634-1638.
12. Ohishi M, Rakugi H, Ogihara T. Association between a delation polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. NEJM. 1994;331:1097. Letter.
13. Iwai N., Ohmichi N., Nakamura Y., et al. DD genotype of the angiotensin-converting enzyme is a risk factor for left ventricular hypertrophy. Circulation. 90:1994;2622-2628.
14. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644.
15. Tiret L., Kee F., Poirier O., et al. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet. 341:1993;991-992.
16. Ludwig EH, Cornell PS, Anderson JF, et al. The ACE insertion/deletion polymorphism is independently associated with myocardial infarction and body mass index but not with stenosis. Circulation. 1993;88(suppl I):I-364. Abstract.
17. Gharavi A.G., Lipkowitz M.S., Diamond J.A., et al. Deletion polymorphism of the angiotensin-converting enzyme gene is independently associated with left ventricular mass and geometric remodeling in systemic hypertension. Am J Cardiol. 77:1996;1315-1319.
18. Perticone F., Ceravolo R., Cosco C., et al. Deletion polymorphism of angiotensin-converting enzyme gene and left ventricular hypertrophy in Southern Italian patients. J Am Coll Cardiol. 29:1997;365-369.
19. Sudoh T., Kangawa K., Minamino N., Matsuo H. A new natriuretic peptide in porcine brain. Nature. 332:1988;78-81.
20. Minamino N., Aburaya M., Ueda S., et al. The presence of brain natriuretic peptide of 12,000 daltons in porcine heart. Biochem Biophys Res Commun. 155:1988;740-746.
21. Kohno M., Horio T., Yoshiyama M., Takeda T. Accelerated secretion of brain natriuretic peptide from the hypertrophied ventricles in experimental malignant hypertension. Hypertension. 19:1992;206-211.
22. Kohno M., Fukui T., Horio T., et al. Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension. Am J Physiol. 266:1994;1-8.
23. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med. 92:1992;29-34.
24. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor . Am J Med. 98:1995;257-265.
25. World Health Organization. Arterial hypertension: report of a WHO expert committee. WHO Technical Report Series, 628. Geneva: World Health Organization, 1978.
26. Shanmugan V., Sell K.W., Saha B.K. Mistyping ACE heterozygotes. PCR Methods Appl. 3:1993;120-121.
27. Fogarty D.G., Maxwell A.P., Doherty C.C., et al. ACE gene typing. Lancet. 343:1994;851.
28. Rigat B., Hubert C., Corvol P., et al. PCR deletion of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res. 20:1992;1433.
29. Ueda S., Heely R.P., Lees K.R., et al. Mistyping of the human angiotensin-converting enzyme gene polymorphism frequently, causes and possible methods to avoid errors in typing . J Mol Endocrinol. 17:1996;27-30.
30. Sahn D.J., De Maria A., Kisslo J., et al. Recommendations regarding quantitation in M-mode echocardiography results of a survey of echocardiographic measurements . Circulation. 58:1978;1072-1083.
31. Troy B.L., Pombo J., Rackley C.E. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation. 45:1972;602-611.
32. Wallenstein S., Zucker C.L., Fleiss J.L. Some statistical methods useful in circulation research. Circ Res. 47:1980;1-9.
33. Greenhouse S.W., Geisser S. On methods in the analysis of profile data. Psychometrika. 24:1954;95-102.
34. Sasaki M., Oki T., Iuchi A., et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension M-mode and pulsed Doppler echocardiographic studies . J Hypertens. 14:1996;1403-1408.
35. Ueda S., Elliott H.L., Morton J.J., et al. Enhanced pressor response to angiotensin I in normotensive men with the deletion genotype (DD) for angiotensin-converting enzyme. Hypertension. 25:1995;1266-1269.
36. Danser A.H.J., Schalekamp M.A.D.H., Bax W.A., et al. Angiotensin-converting enzyme in the human heart. Circulation. 92:1995;1387-1388.